Editor’s Note
The first four months of 2026 have posed a design question that keeps me up at night: when an entire field decides to shed its identity and reach for institutional legibility, what gets lost in the translation — and does it matter?
This issue is an attempt to sit with that tension — between psychedelic origin and pharmaceutical ambition, between counterculture and clinic — and look at what it's producing visually, linguistically, and culturally. That, as far as I'm concerned, is the design story of this moment.
DESIGN & CREATIVITY
The science of creativity is catching up to what designers have always suspected — and the tools, institutions, and aesthetic movements shifting around us are making the conversation urgent.
Microdosing psilocybin improves the quality of creative ideas — but not the quantity
A mega-analysis pooling data from three double-blind, placebo-controlled trials (N=171) led by Luisa Prochazkova at Leiden University found that psilocybin microdoses improved the quality (originality-to-fluency ratio) of divergent thinking without increasing the speed or volume of ideas generated. The researchers theorize that microdosing relaxes the brain’s top-down pattern reliance, allowing earlier access to remote conceptual associations — which, if you work creatively, sounds less like a pharmacological effect and more like a description of a good working state. A notable placebo effect was also observed, particularly among prior psychedelic users, which raises its own questions about expectation and creative confidence. PsyPost / Neuropharmacology
Brain networks behind scientific creative thinking mapped for the first time
A Penn State neuroimaging study scanned 47 STEM students in the act of generating novel hypotheses and found that scientific creative thinking recruits the same three networks involved in general creativity — the default mode network, the salience network, and a semantic control region — with cross-network communication increasing precisely as within-network activity decreases. What’s notable for designers isn’t just the brain science: it’s the suggestion that the conditions for creative insight are structural, not exceptional. The researchers argue the findings could reshape how STEM curricula are designed — a reminder that education is always also a design problem. PsyPost / Psychology of Aesthetics, Creativity, and the Arts
Imaginarium — the first scientific conference on psychedelics and creativity
In January 2026, UC San Diego's Center for MINDS and the Arthur C. Clarke Center for Human Imagination co-hosted what may be the first academic conference dedicated specifically to psychedelics and creativity — featuring artists Alex and Allyson Grey, multimedia journalist Hamilton Morris, and psychedelic comedian Shane Mauss alongside researchers. The framing was pointed: clinical psychedelic research is accelerating, but imagination and creativity are being left behind as scientific priorities. For designers, this is the academic world catching up to a conversation the creative community has been having for years — and it signals that creativity is becoming a legitimate scientific object of study in its own right, not merely a side effect of therapy. District216 / UCSD
REBRAND RADAR
Something has shifted. In the first quarter of 2026, the psychedelic sector executed a series of corporate rebrands — and the visual logic is unmistakable. Companies that built their identity around the language of psychedelia are mostly replacing it with Latinized, pharmaceutical-grade nomenclature: abstract, authoritative, legible to regulators and institutional investors alike. This feels like a statement about where these companies believe they belong.
MindMed → Definium Therapeutics (effective January 2026)
The most prominent rebrand of the quarter. Mind Medicine dropped its explorer-era identity and relaunched as Definium Therapeutics, a compound of two Latin roots: definio (to define, to bound — scientific precision) and infinitum (openness to possibility). The company enters 2026 with three Phase 3 readouts of its LSD-derived compound DT120 expected within the year. Business Wire
Cybin → Helus Pharma (effective January 2026)
Cybin rebranded as Helus Pharma and simultaneously moved from NYSE American to Nasdaq. The name is pronounced “Heal Us” — an unusually direct therapeutic declaration. The company rang the Nasdaq opening bell with the new brand displayed in Times Square. Its lead program HLP003 (deuterated psilocybin analog) carries FDA Breakthrough Therapy Designation for major depressive disorder. Helus Pharma IR
Mydecine Innovations Group → Noveris Health Sciences (effective February 2026)
Quiet but telling: the Canadian psychedelic biotech swapped both its name and ticker (MYCO → NVRS on the CSE). No detailed rationale was disclosed, but Noveris — suggesting novelty and a broader health sciences orientation — continues the sector-wide pattern of erasing psychedelic-specific nomenclature. Newsfile Corp
Entheon Biomedical → STRYK Brands (announced January 2026, pending)
Entheon Biomedical represents an outlier in this group. Rather than evolving its position within psychedelic medicine, the company is pivoting away from the sector entirely. Following a proposed reverse takeover by nutraceutical company Nutravisor, Entheon is expected to rebrand as STRYK Brands, shifting its focus toward consumer performance health products. Where others are moving toward clinical models, Entheon is repositioning closer to the consumer wellness and performance space. Newsfile Corp / Entheon
atai Life Sciences + Beckley Psytech → AtaiBeckley (merger closed November 2025; fully active Q1 2026)
The merger-driven rebrand: two established players combined into a single identity that honors both legacies. AtaiBeckley enters 2026 with BPL-003 (5-MeO-DMT intranasal spray) heading toward Phase 3, financial runway into 2029, and a place on the NASDAQ Biotechnology Index. AtaiBeckley
Carhart-Harris Lab (new branding and website launch, January 2026)
At a moment when much of the psychedelic field is adopting the visual language of traditional pharma — clean, restrained, and clinical — the Carhart-Harris Lab moves in a different direction.
The academic collective led by Dr. Robin Carhart-Harris at UCSF recently launched a new website and identity that feels closer to culture and art than institutional science. A full-bleed black background, a deep crimson radial bloom, and a stark all-caps wordmark create a system that is both minimal and expressive. At its centre sits a simple orbital form — a circle bisected by a fine line — reading as neuron, sun, lens, and psychedelic orb at once.
The tagline, “Science at the edge. Therapy in the making.”, reflects the system precisely: a space still in formation, where research and application meet. In a field negotiating its place between counterculture and clinic, the lab suggests that scientific credibility does not have to come at the expense of aesthetic risk. carhartharrislab.com
Disclosure: branding by Alexandra Plesner, author of this newsletter.
Mission Within Foundation → Mission to Live Foundation (effective March 2026)
The foundation that funds psychedelic therapy scholarships for veterans and first responders has rebranded while fully adopting the new name and identity. The name change does real linguistic work: from the blunt urgency of survivalist language to something more introspective and therapeutic. Less emergency, more invitation — a reframe that mirrors the shift happening across the broader psychedelic sector, but arrived at through mission rather than market pressure. missiontolivefoundation.org
Disclosure: brand identity co-designed by Alexandra Plesner and Marissa Feinberg, founder of Triple Bottom Why and PSYCA.
The naming pattern across Definium, Helus, and Noveris is worth sitting with. These are pharmaceutical names — Latin roots, no psychedelic associations, nothing that signals origin. In design terms, it’s a classic brand maturity move: the challenger phase gives way to the institutional phase. The question is whether anything essential gets lost in translation.
SPOTLIGHT
Blossom → More Blossom (new website and logo relaunch, April 2026)
Blossom has become More Blossom—and this is what a serious relaunch looks like.
The platform now positions itself as a “unified intelligence layer” for psychedelic research. That shift could have felt inflated. It doesn’t. The product and the design both carry the weight.
The new mark is a geometric red-orange symbol: two interlocking B-forms that read as data intersection and organic growth. It’s restrained, legible, and does the job across scales. The broader design language follows through—clean, structured, and confident in complexity.
One of the most considered relaunches I’ve seen in years. I asked Floris a few questions to get closer to how this came together:
Why rebuild?
”Blossom had been running on WordPress for over seven years. It served us well, but the database had outgrown what plugins could handle. I rebuilt the entire platform from scratch on a modern stack (Sanity, Next.js, Vercel) so the data architecture could actually match what researchers and organisations need: structured metadata across 2,500+ papers, trials, compounds, stakeholders, and more. It was a solo project on the development side, though I've had collaborators on content and analysis over the years.”
What changed?
”Everything, really. The database is deeper and more connected. You can now explore research by compound, country, topic, or stakeholder, and cross-reference between them. There are new tools like the Atlas (a visual research landscape map), a research network showing co-authorship links, outcome data comparisons, and monthly research recaps.”
Identity shift?
”The old Blossom mark had done its job, but it looked like it belonged to the WordPress era. The new identity is cleaner and more confident. The “B” icon works at small sizes (favicons, avatars), the wordmark is set in Caladea, and the colour palette centres on a bold orange. It reflects where the platform is now: less blog, more intelligence layer.”
Check out the new platform and experience awe: moreblossom.com
RESEARCH WORTH NOTING
Compass Pathways Phase 3 — the quarter's most significant clinical milestone. Compass Pathways' Phase 3 COMP006 trial of COMP360 (synthetic psilocybin) met its primary endpoint in treatment-resistant depression, showing a statistically significant 3.8-point MADRS reduction vs. control, with effects beginning the day after administration — the company is targeting an NDA submission in Q4 2026 and a potential 2027 launch. BioPharma Dive For readers who want the full research and regulatory picture — Phase 2 results, DEA quota changes, policy developments across states — The Microdose and Blossom cover that terrain with depth and rigor; this newsletter will point you there rather than duplicate their work.
Mind FLUX — the first study designed for real-world creative problem solving
Led by Dr. Manesh Girn, Dr. Manoj Doss and Dr. Greg Fonzo at the University of Charmaine & Gordon McGill Center for Psychedelic Research & Therapy with the Center for MINDS, Mind FLUX is the first controlled psilocybin study built specifically to test processing fluency — the mental state most directly linked to creative insight and flexible thinking — across three phases: a survey of innovators, an fMRI clinical study, and real-world application with professionals testing psilocybin's effect on actual creative work rather than proxy tasks like brick uses. This matters to designers precisely because it moves the research object from the lab abstraction to the thing itself. Dr. Girn is also a confirmed speaker at the Psychedelics Design Conference in November this year. Read the full article by our friend and collaborator Dennis Walker on Lucid News
NEWS FROM PSYCHEDELICS DESIGN
Speaking at Tryp Expo Berlin — May 15–17, Funkhaus Berlin. Alexandra Plesner will be on stage at Tryp Expo — Europe's newest psychedelic science and wellness gathering — alongside Dr. Sam Gandy in a talk on Symbiotic Futures. Use PSYDESIGNTRYP for 10% off your ticket <3
Psychedelics Design Monthly launches today. This is the first issue of what will be a monthly digest — each edition covering the most significant developments in design culture, creative practice, and visual identity across the psychedelic field. Thank you for being here from the start.
The 2026 Psychedelics Design Awards are open. The world's first design competition recognising creative excellence in the psychedelic space returns for 2026 — across eight categories including Visual Design & Branding, Storytelling, Audio Experience, Architectural & Space, and Mushroom of the Year. Open to designers, studios, researchers, artists, and students. Submit your work
Research study open: “Psychedelics and the Creative Process.” We are conducting ongoing research into how designers, artists, and makers experience the relationship between psychedelics and their creative work. If you work in a creative field and have something to contribute, we want to hear from you. Details at www.psychedelics.design/survey If you are interested in a partnership, please do get in touch via info@psychedelics.design
Contribute to Psy*Design Monthly. If you have research, work, or a perspective that belongs in this newsletter, reach out. This publication is a conversation, not a broadcast.
FROM OUR PARTNERS
Music for Mushrooms, a narrative feature documentary by last year’s speaker and judge East Forest exploring music, ceremony, and inner healing, is now available for a limited time on YouTube.
Nutritious, a NYC-raised cultural alchemist — artist, DJ, producer, and A&R at Liquid Culture Records — has just released Freefall, a three-track EP featuring “Freefall,” “Freefall” (Chill Mix), and “Spiral.” Centered on the themes of love, passion, and faith, the EP explores the exquisite vertigo of surrendering to a force that pulls harder than the earth itself — a coordinate in the deep atmosphere where the weight of control dissolves, leaving only the rush of the descent. Nutritious is also the creative mind behind our exclusive podcast intro.
“Nutritious has delivered a kaleidoscopic, high-fidelity journey that feels like a vivid, iridescent dream. It is, quite simply, one of the most immersive listening experiences of the year.” — Psychedelics Design
We are looking for partners and sponsors for the 2026 Psychedelics Design Festival & Awards, with a global audience of designers, researchers, creatives, and practitioners working at the intersection of psychedelics and creative culture. If your organisation wants to reach this community — whether in research, clinical environments, brand strategy, education, or creative practice — we would love to hear from you. Get in touch
"The real voyage of discovery consists not in seeking new landscapes, but in having new eyes".
Marcel Proust, the fifth volume of In Search of Lost Time (also known as Remembrance of Things Past), specifically La Prisonnière.
To share, forward freely. To unsubscribe, manage your subscription via Substack.